AstraZeneca: Fasenra Approved for Treatment of Children Aged 6 to 11 With Severe Asthma
April 12, 2024
April 12, 2024
WILMINGTON, Delaware, April 12 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca's FASENRA(R) (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1
AstraZeneca's FASENRA(R) (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1